**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Pankaj Malhotra

**Main Body of the Abstract**
Limited research exists on AL amyloidosis cases in low and middle-income countries (LMIC).  We retrospectively analyzed AL amyloidosis patients treated at a tertiary care center in North India from January 2010 to July 2022. All patients had confirmed AL amyloidosis through histopathological examination. Patients with concomitant multiple myeloma were excluded. We examined clinical presentation, investigations, and treatment details. Hematologic response criteria included complete response (CR), very good partial response (VGPR), and partial response (PR), while renal response involved a >30% reduction in 24-hour proteinuria. We analyzed 59 patients with a median age at diagnosis of 56 years (range 38–78 years); 59.3% were males. The median symptom duration was 6 months (range 1–18 months). Common presentations included proteinuria and/or renal dysfunction (67.7%), congestive heart failure (28.8%), peripheral neuropathy (13.5%), purpura and skin involvement (10.1%), and bleeding manifestations (10.1%). Renal and cardiac involvement occurred in 77.9% and 50.8%, respectively. The majority (81.3%) exhibited the lambda monoclonal light chain type. Bortezomib-based therapy was received by most patients (84.7%), while 4 each underwent autologous stem cell transplantation and daratumumab-based combination therapy. Median follow-up was 28 months (range 1–96 months). Hematologic response occurred in 72.8%, with 54.2% achieving CR/VGPR. Renal response was observed in 40.6%. During follow-up, 54.2% of patients died, resulting in an overall survival (OS) of 45.7%. AL amyloidosis poses significant morbidity and mortality even at a tertiary care center in LMIC. Early diagnosis and prompt initiation of treatment with novel agents are crucial for improving outcomes.



Clinical profile and treatment outcomes in primary (AL) amyloidosis from low- and middle-income country (LMIC) PA119 (#299)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.